SCYNEXIS Ibrexafungerp 2022: Novel Oral/IV Antifungal

SCYNEXIS presents ibrexafungerp (BREXAFEMME), the first representative of a novel oral/intravenous antifungal portfolio designed to treat difficult-to-treat and life-threatening infections. The November 2022 presentation outlines the clinical validity, FDA approval status, and commercialization strategy for this innovative antifungal candidate.